Published in Cancer Biol Ther on January 12, 2006
Intelligent design: combination therapy with oncolytic viruses. Mol Ther (2009) 1.68
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer (2011) 1.17
Impact of tumor microenvironment on oncolytic viral therapy. Cytokine Growth Factor Rev (2010) 1.13
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther (2008) 1.11
Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev (2009) 1.10
Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol (2010) 1.07
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res (2011) 1.00
HSV Recombinant Vectors for Gene Therapy. Open Virol J (2010) 0.99
The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma. Br J Cancer (2013) 0.88
Hedgehog signaling in hepatocellular carcinoma: novel therapeutic strategy targeting hedgehog signaling in HCC. Cancer Biol Ther (2006) 0.87
Clld7, a candidate tumor suppressor on chromosome 13q14, regulates pathways of DNA damage/repair and apoptosis. Cancer Res (2010) 0.87
Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. Br J Cancer (2012) 0.86
Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer. Clin Cancer Res (2014) 0.85
Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus. J Gene Med (2010) 0.84
Tunneling nanotubes: an alternate route for propagation of the bystander effect following oncolytic viral infection. Mol Ther Oncolytics (2016) 0.84
Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation. Cancer Gene Ther (2011) 0.82
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances. Oncolytic Virother (2016) 0.79
What's the place of immunotherapy in malignant mesothelioma treatments? Cell Adh Migr (2010) 0.78
Combining chemotherapy with virotherapy: a novel treatment strategy for malignant pleural mesothelioma. Cancer Biol Ther (2006) 0.76
Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment. Clin Epigenetics (2016) 0.75
Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs. Oncolytic Virother (2013) 0.75
Chemovirotherapy of Pancreatic Adenocarcinoma by Combining Oncolytic Vaccinia Virus GLV-1h68 with nab-Paclitaxel Plus Gemcitabine. Mol Ther Oncolytics (2017) 0.75
Oncolytic virotherapy for human malignant mesothelioma: recent advances. Oncolytic Virother (2015) 0.75
Immunotherapy for malignant pleural mesothelioma: current status and future directions. Transl Lung Cancer Res (2017) 0.75
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol (2003) 11.22
Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene (2003) 10.74
The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells. Proc Natl Acad Sci U S A (1992) 4.90
Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem (1981) 3.01
Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc Natl Acad Sci U S A (1994) 2.94
Cisplatin and platinum drugs at the molecular level. (Review). Oncol Rep (2003) 2.49
Demographic patterns for mesothelioma in the United States. J Natl Cancer Inst (1987) 2.01
Mammalian GADD34, an apoptosis- and DNA damage-inducible gene. J Biol Chem (1997) 1.85
Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther (2002) 1.51
Projections of asbestos-related disease 1980-2009. J Occup Med (1983) 1.49
Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Ther (2002) 1.36
Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther (2002) 1.26
Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J (2004) 1.24
Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia (1999) 1.13
Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther (1999) 1.12
Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res (1999) 1.09
Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res (2004) 1.08
Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. Clin Cancer Res (2004) 1.04
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol (1994) 1.02
Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer (2004) 1.00
Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res (1997) 0.99
Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol (1991) 0.96
Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep (1985) 0.94
Regulation of herpes simplex virus 1 replication using tumor-associated promoters. Ann Surg (2002) 0.93
Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Clin Cancer Res (2000) 0.91
Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer. Ann Surg (2002) 0.90
Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol (1994) 0.89
Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer (2005) 0.88
Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. J Urol (2005) 0.88
The in-vitro and in-vivo efficacy of cisplatin and analogues in the treatment of herpes simplex virus-II infections. J Antimicrob Chemother (1987) 0.84
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg (2002) 8.30
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg (2011) 5.14
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol (2010) 4.52
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol (2008) 4.37
Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol (2002) 4.16
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol (2011) 3.92
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. J Thorac Cardiovasc Surg (2009) 3.76
Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg (2006) 3.76
A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol (2008) 3.30
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg (2003) 3.14
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg (2008) 2.93
Results of chest wall resection and reconstruction with and without rigid prosthesis. Ann Thorac Surg (2006) 2.77
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol (2011) 2.58
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol (2006) 2.58
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol (2008) 2.56
Robotic assistance for video-assisted thoracic surgical lobectomy: technique and initial results. J Thorac Cardiovasc Surg (2006) 2.53
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol (2009) 2.52
Patterns of surgical care of lung cancer patients. Ann Thorac Surg (2005) 2.51
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 2.48
Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst (2013) 2.45
Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg (2009) 2.44
American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol (2007) 2.41
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc (2011) 2.39
Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg (2003) 2.36
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol (2003) 2.36
Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. Ann Thorac Surg (2008) 2.33
Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg (2009) 2.32
Operative drainage following pancreatic resection: analysis of 1122 patients resected over 5 years at a single institution. Ann Surg (2013) 2.29
Analysis of the extent of resection for adenocarcinoma of the gallbladder. Ann Surg Oncol (2008) 2.28
Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol (2009) 2.27
Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy. Ann Surg (2009) 2.27
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol (2009) 2.26
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS One (2007) 2.25
The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg (2007) 2.23
Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg (2007) 2.22
The use of fresh frozen plasma after major hepatic resection for colorectal metastasis: is there a standard for transfusion? J Am Coll Surg (2003) 2.20
Combined blunt-clamp dissection and LigaSure ligation for hepatic parenchyma dissection: postcoagulation technique. J Am Coll Surg (2009) 2.19
A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol (2010) 2.15
Video-assisted thoracoscopic surgery (VATS) lobectomy: catastrophic intraoperative complications. J Thorac Cardiovasc Surg (2011) 2.11
Diagnosis, management, and outcomes of 115 patients with hepatic hemangioma. J Am Coll Surg (2003) 2.09
Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg (2003) 2.06
Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg (2003) 2.05
Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res (2011) 2.03
Optimum lymphadenectomy for esophageal cancer. Ann Surg (2010) 2.01
(124)I-huA33 antibody PET of colorectal cancer. J Nucl Med (2011) 2.01
Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg (2010) 1.98
Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg (2003) 1.97
The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma. J Am Coll Surg (2004) 1.97
The American Board of Thoracic Surgery: update. J Thorac Cardiovasc Surg (2012) 1.96
A prediction model for pathologic N2 disease in lung cancer patients with a negative mediastinum by positron emission tomography. J Thorac Oncol (2013) 1.95
Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg (2009) 1.94
Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas? Hepatology (2012) 1.94
Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. Ann Thorac Surg (2009) 1.88
Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg (2007) 1.86
Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg (2008) 1.85
Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer (2002) 1.85
Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol (2010) 1.80
Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg (2003) 1.79
A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg (2008) 1.76
Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg (2002) 1.75
Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Ann Surg Oncol (2011) 1.75
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol (2005) 1.73
Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg (2012) 1.71
Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Mol Ther (2007) 1.71
Laparoscopic adrenalectomy for isolated adrenal metastasis. Ann Surg Oncol (2007) 1.71
Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. J Thorac Oncol (2011) 1.69
Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. J Thorac Oncol (2011) 1.67
Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biol Ther (2004) 1.67
Hepatocellular carcinoma: current surgical management. Gastroenterology (2004) 1.66
Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer (2006) 1.66
Management of primary liver sarcomas. Cancer (2007) 1.65
Caudate hepatectomy for cancer: a single institution experience with 150 patients. J Am Coll Surg (2005) 1.64
Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Arch Surg (2007) 1.63
Mediastinoscopy: an endangered species? J Clin Oncol (2005) 1.62
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology (2011) 1.61
Predictors of outcomes after surgical treatment of synchronous primary lung cancers. J Thorac Oncol (2010) 1.61
Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol (2006) 1.60
Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg (2005) 1.60
Contemporary experience with postpancreatectomy hemorrhage: results of 1,122 patients resected between 2006 and 2011. J Am Coll Surg (2012) 1.58
Major hepatectomy with simultaneous pancreatectomy for advanced hepatobiliary cancer. J Am Coll Surg (2004) 1.58
Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg (2013) 1.58
Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg (2011) 1.57
Dietary inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-deficient mice. Proc Natl Acad Sci U S A (2010) 1.56
Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery (2007) 1.54
Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012. Hum Gene Ther (2013) 1.54
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther (2009) 1.54